Traci Turner, MD
Internal Medicine · Cincinnati, OHNPI 1285675884
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $89 of the $100 with a category attached, or 89.0%. Amgen accounts for 89.0% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for internal medicine clinicians in OH, where the typical reported total is $164.
Across 2 payments — averaging $50.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$89
- Regeneron Healthcare Solutions, Inc.$11
Across 86 payments — averaging $7527.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$296K
- Regeneron$131K
- AstraZeneca$115K
- Roche Molecular Systems, Inc.$49K
- Amgen$48K
- Astrazeneca UK Limited$9K
What the payments were for
- Food & beverage$8989%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 1 | $89 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
How this compares
$100 in reported general payments places this provider in the 40th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 181 | $235,786 |
| Praluent PenAlirocumab | 60 | $58,103 |
| Niacin ErNiacin | 24 | $4,596 |
| Ezetimibe | 174 | $3,745 |
| Rosuvastatin Calcium | 231 | $2,984 |
| Atorvastatin Calcium | 86 | $809 |
| Allopurinol | 15 | $194 |
| Simvastatin | 17 | $184 |
| Lisinopril | 20 | $167 |
| Amlodipine Besylate | 13 | $68 |
| Ramipril | 12 | $5 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Cincinnati
- Lisa LarkinCincinnati$276K
- Vincent MartinCincinnati$261K
- Kay JohnsonCincinnati$184K
- Jason HatfieldCincinnati$72K
- Rajbir MinhasCincinnati$62K
- Hassan MalikAkron$1.7M
- Cyrus HarrisCleveland$726K
- Nina DeepWesterville$614K
- Necklall KhooblallAustintown$448K
- Daniel WeissMentor$406K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.